Review article · 2025 · Open access

Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis

Johannes Schneider‐Thoma, Tasnim Hamza, Konstantina Chalkou, Spyridon Siafis, Shimeng Dong, Irene Bighelli, Wulf‐Peter Hansen, Elfriede Scheuring, John M. Davis, Josef Priller, Pierre Baumann, Robert R. Conley and 12 more

The Lancet Psychiatry, 12(4), 254–265 · Published 26 February 2025 · DOI 10.1016/s2215-0366(25)00001-x

Open full textCite this paper

In brief

“Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis” is a 2025 review article by Johannes Schneider‐Thoma and 23 co-authors, published in The Lancet Psychiatry. OpenAlex counts 49 citations as of 20 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet Psychiatry.

Citations
49
Most cited in
2026 (31)
Field-weighted impact
5.36
References
53
Authors
24

Abstract

BACKGROUND: Clozapine is recommended by national and international guidelines for people with treatment-resistant schizophrenia. However, available meta-analyses of randomised controlled trials have not shown superior efficacy of clozapine when compared with other second-generation antipsychotics, with heterogeneity identified between the original studies. We aimed to use individual patient data (IPD) to account for potential reasons of variability and to synthesise an adjusted estimate for the difference in efficacy between clozapine and other second-generation antipsychotics for treatment-resistant schizophrenia. METHODS: In this systematic review and IPD meta-analysis, we searched the Cochrane Schizophrenia Group's Study-Based Register from inception to Jan 24, 2024, and previous reviews for blinded randomised controlled trials comparing clozapine with other second-generation antipsychotics in participants with treatment-resistant schizophrenia. Trials were eligible if they included patients with treatment-resistant schizophrenia and had a duration of at least 6 weeks. IPD were requested from trial investigators. The primary outcome was change in overall schizophrenia symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) between clozapine and other second-generation antipsychotics after 6-8 weeks of treatment. The effect size measure for the primary outcome was mean difference with 95% credible interval (CrI). We fitted a Bayesian random-effects IPD meta-regression model that included duration of illness, baseline severity, and sex as potential prognostic factors or treatment effect modifiers. Confidence in the evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). People with lived experience of mental illness were involved in this study. This study is registered with PROSPERO, CRD42021254986. FINDINGS: We screened 13 876 references and included 19 studies with data for 1599 participants; IPD were available for 12 of 19 trials (n=1052; mean age 37·67 years [SD 11·24; range 10-66]; 348 [33·08%] women and 704 [66·92%] men). Data on ethnicity were not available. The estimated mean difference in change from baseline PANSS total score was -0·64 points (95% CrI -3·97 to 2·63; τ=2·68) in favour of other second-generation antipsychotics. Shorter duration of illness and higher baseline severity were prognostic factors associated with a larger reduction in symptoms, but neither those factors nor sex were found to modify the relative effect between clozapine and other second-generation antipsychotics. The confidence in the evidence was graded as very low. INTERPRETATION: This IPD meta-analysis found a small and uncertain advantage of other second-generation antipsychotics, mainly olanzapine and risperidone, and so did not provide evidence for superior efficacy of clozapine compared with other second-generation antipsychotics in treatment-resistant schizophrenia. It is limited by unavailability of IPD for some studies, uncaptured sources of variance, and uncertainty due to…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Schneider‐Thoma, J., Hamza, T., Chalkou, K., Siafis, S., Dong, S., Bighelli, I., Hansen, W., Scheuring, E., Davis, J. M., Priller, J., Baumann, P., Conley, R. R., Cordes, J., Kelly, D., Kluge, M., Kumra, S., Lewis, S. W., Meltzer, H. Y., Naber, D., . . . Leucht, S. (2025). Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis. The Lancet Psychiatry, 12(4), 254–265. https://doi.org/10.1016/s2215-0366(25)00001-x

MLA 9

Schneider‐Thoma, Johannes, et al. “Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis.” The Lancet Psychiatry, vol. 12, no. 4, 2025, pp. 254–265. https://doi.org/10.1016/s2215-0366(25)00001-x.

Chicago

Schneider‐Thoma, Johannes, Tasnim Hamza, Konstantina Chalkou, Spyridon Siafis, Shimeng Dong, Irene Bighelli, Wulf‐Peter Hansen, et al. 2025. “Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis.” The Lancet Psychiatry 12 (4): 254–265. https://doi.org/10.1016/s2215-0366(25)00001-x.

Harvard

Schneider‐Thoma, J. et al. (2025) ‘Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis’, The Lancet Psychiatry, 12(4), pp. 254–265. doi:10.1016/s2215-0366(25)00001-x.

IEEE

J. Schneider‐Thoma et al., “Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis,” The Lancet Psychiatry, vol. 12, no. 4, pp. 254–265, 2025, doi: 10.1016/s2215-0366(25)00001-x.

BibTeX

@article{schneiderthoma2025efficacy,
  title     = {{Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis}},
  author    = {Schneider‐Thoma, Johannes and Hamza, Tasnim and Chalkou, Konstantina and Siafis, Spyridon and Dong, Shimeng and Bighelli, Irene and Hansen, Wulf‐Peter and Scheuring, Elfriede and Davis, John M. and Priller, Josef and Baumann, Pierre and Conley, Robert R. and Cordes, Joachim and Kelly, Deanna and Kluge, Michael and Kumra, Sanjiv and Lewis, Shôn W. and Meltzer, Herbert Y. and Naber, Dieter and Schooler, Nina R. and Volavka, Jan and Wahlbeck, Kristian and Salanti, Georgia and Leucht, Stefan},
  journal   = {The Lancet Psychiatry},
  year      = {2025},
  volume    = {12},
  number    = {4},
  pages     = {254--265},
  doi       = {10.1016/s2215-0366(25)00001-x},
  url       = {https://doi.org/10.1016/s2215-0366(25)00001-x}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • clozapine
  • atypical antipsychotics
  • treatment-resistant schizophrenia
  • antipsychotic efficacy
  • PANSS
  • prognostic factors
  • disease duration
  • baseline symptom severity

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Schneider‐Thoma, J., Hamza, T., Chalkou, K., Siafis, S., Dong, S., Bighelli, I., Hansen, W., Scheuring, E., Davis, J. M., Priller, J., Baumann, P., Conley, R. R., Cordes, J., Kelly, D., Kluge, M., Kumra, S., Lewis, S. W., Meltzer, H. Y., Naber, D., . . . Leucht, S. (2025). Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis. The Lancet Psychiatry, 12(4), 254–265. https://doi.org/10.1016/s2215-0366(25)00001-x

How many times has this paper been cited?

49 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Lancet Psychiatry: sign in and open the full text from this page.

Who wrote this paper?

Johannes Schneider‐Thoma, Tasnim Hamza, Konstantina Chalkou, Spyridon Siafis, Shimeng Dong, Irene Bighelli, Wulf‐Peter Hansen, Elfriede Scheuring, John M. Davis, Josef Priller, Pierre Baumann, Robert R. Conley and 12 more.

What is the DOI of this paper?

10.1016/s2215-0366(25)00001-x, permanently at https://doi.org/10.1016/s2215-0366(25)00001-x. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.